Achieve Life Sciences (Nasdaq:ACHV) - Aandelenkoers, Nieuws & Analyse

ACHV Overzicht aandelen

Achieve Life Sciences, Inc., een farmaceutisch bedrijf in een klinische fase, ontwikkelt en verkoopt cytisinicline voor stoppen met roken en nicotineverslaving.

Over het bedrijf

ACHV fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 98.6% onder onze schatting van de reële waarde

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Achieve Life Sciences, Inc. Concurrenten

Verastem

NasdaqCM:VSTM

US$150.5m

Sagimet Biosciences

NasdaqGM:SGMT

US$185.4m

Black Diamond Therapeutics

NasdaqGS:BDTX

US$183.9m

Adverum Biotechnologies

NasdaqCM:ADVM

US$160.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Achieve Life Sciences
Historische aandelenkoersen
Huidige aandelenkoers	US$5.12
52 Week Hoogtepunt	US$5.98
52 Week Laag	US$3.03
Bèta	1.57
11 maand verandering	-0.39%
3 maanden verandering	13.53%
1 Jaar Verandering	19.07%
33 jaar verandering	-37.25%
5 jaar verandering	-69.16%
Verandering sinds IPO	-99.42%

Recent nieuws en updates

Recent updates

Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

Jun 29

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

Apr 04

Is Achieve Life Sciences (NASDAQ:ACHV) Weighed On By Its Debt Load?

Mar 22

Is Achieve Life Sciences (NASDAQ:ACHV) In A Good Position To Deliver On Growth Plans?

Sep 27

We Think Achieve Life Sciences (NASDAQ:ACHV) Needs To Drive Business Growth Carefully

Jun 14

We're Keeping An Eye On Achieve Life Sciences' (NASDAQ:ACHV) Cash Burn Rate

Mar 01

Achieve Life Sciences prices stock offering at $7; shares down 2%

Dec 03

Achieve Life Sciences launches equity offering

Nov 30

Rendement voor aandeelhouders

	ACHV	US Biotechs	US Markt
7D	8.2%	1.6%	2.3%
1Y	19.1%	23.6%	35.1%

Rendement versus industrie: ACHV presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 21.4 % opleverde.

Rendement versus markt: ACHV presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.5 % opleverde.

Prijsvolatiliteit

Is ACHV's price volatile compared to industry and market?
ACHV volatility
ACHV Average Weekly Movement	5.3%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: ACHV heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van ACHV is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	22	Rick Stewart	www.achievelifesciences.com

Achieve Life Sciences, Inc., een farmaceutisch bedrijf in een klinische fase, ontwikkelt en verkoopt cytisinicline voor stoppen met roken en nicotineverslaving. Het bedrijf biedt cytisinicline aan, een alkaloïde op plantaardige basis die een wisselwerking aangaat met nicotinereceptoren in de hersenen en zo de ernst van nicotineonttrekkingsverschijnselen vermindert. Het heeft een licentie- en leveringsovereenkomst met Sopharma AD en de Universiteit van Bristol Achieve Life Sciences, Inc. is gevestigd in Vancouver, Canada.

Achieve Life Sciences, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Achieve Life Sciences zich tot de beurswaarde?
ACHV fundamentele statistieken
Marktkapitalisatie	US$166.56m
Inkomsten(TTM)	-US$27.54m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-6.4x

Koers/Winstverhouding

Is ACHV overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ACHV resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$27.54m
Inkomsten	-US$27.54m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 07, 2024

Winst per aandeel (EPS)	-0.80
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	41.6%

Hoe presteerde ACHV op de lange termijn?

Bekijk historische prestaties en vergelijking

ACHV Overzicht aandelen

Beloningen

Risicoanalyse

Achieve Life Sciences, Inc. Concurrenten

NasdaqCM:VSTM

US$150.5m

NasdaqGM:SGMT

US$185.4m

NasdaqGS:BDTX

US$183.9m

NasdaqCM:ADVM

US$160.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Achieve Life Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Achieve Life Sciences, Inc Promotes Jaime Xinos to Chief Commercial Officer

Achieve Life Sciences, Inc. Announces Appointment of Mark L. Rubinstein as Head of Medical Affairs

Achieve Life Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

New minor risk - Profitability

Achieve Life Sciences, Inc. Announces CEO Changes

Recent updates

Achieve Life Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Achieve Life Sciences, Inc Promotes Jaime Xinos to Chief Commercial Officer

Achieve Life Sciences, Inc. Announces Appointment of Mark L. Rubinstein as Head of Medical Affairs

Achieve Life Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

New minor risk - Profitability

Achieve Life Sciences, Inc. Announces CEO Changes

New minor risk - Profitability

Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence

Achieve Life Sciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement

Achieve Life Sciences, Inc. Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes

New minor risk - Profitability

Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

Achieve Life Sciences, Inc., Annual General Meeting, Jun 05, 2024

Achieve Life Sciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Price target decreased by 17% to US$19.71

Achieve Life Sciences, Inc. Announces Data from Cytisinicline ORCA Program to Be Presented at the 2024 Society for Research on Nicotine and Tobacco Annual Meeting

Achieve Life Sciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New major risk - Financial position

Achieve Life Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $60.000002 million.

Does Achieve Life Sciences (NASDAQ:ACHV) Have A Healthy Balance Sheet?

New minor risk - Profitability

Price target decreased by 12% to US$24.71

New minor risk - Share price stability

Price target decreased by 8.1% to US$27.57

Achieve Life Sciences, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is Achieve Life Sciences (NASDAQ:ACHV) Using Debt In A Risky Way?

Achieve Life Sciences, Inc. Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

New minor risk - Market cap size

New major risk - Financial position

Achieve Life Sciences, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)

Achieve Life Sciences, Inc. Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial

Forecast to breakeven in 2025

Price target increased by 10% to US$27.43

Executive Chairman exercised options and sold US$69k worth of stock

High number of new directors

Is Achieve Life Sciences (NASDAQ:ACHV) A Risky Investment?

Price target increased by 14% to US$28.33

Achieve Life Sciences, Inc. Announces Last Subject Dosed in Phase 2 Orca-V1 Trial of Cytisinicline for E-Cigarette Cessation

Dialectic Capital Engages in Discussions with Achieve Life Sciences

Achieve Life Sciences, Inc. Announces That the Final Subject of the Company’s Phase 3 ORCA-3 Trial Has Completed Treatment in the Study

Achieve Life Sciences, Inc. Receives Written Notification from the Listing Qualifications Staff of the Nasdaq Stock Market

Consensus revenue estimates fall by 33%

Price target decreased to US$28.13

Achieve Life Sciences, Inc. announced that it expects to receive CAD 18.930777 million in funding

Achieve Life Sciences, Inc. Announces Early Completion of Target Enrollment in Cytisinicline E-Cigarette Cessation Trial

Achieve Life Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

Consensus revenue estimates fall by 33%

Achieve Life Sciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine E-Cigarette Cessation

Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

Achieve Life Sciences Inc. Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine E-Cigarette Users

Price target increased to US$34.13

Achieve Life Sciences Announces Positive Topline Results from Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers

Price target decreased to US$31.50

Achieve Life Sciences, Inc. to Report Q1, 2022 Results on May 12, 2022

Achieve Life Sciences, Inc., Annual General Meeting, May 31, 2022